Company intelligence / Profile preview

Biotech Active

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Active Biotech has several programs in early to mid-stage clinical development. Tasquinimod is being evaluated for hematological cancers, laquinimod for inflammatory eye diseases, and naptumomab estafenatox (licensed to NeoTX) is under investigation for solid tumors. No late-stage or commercialized products are reported as of now.

Therapeutic areas: OphthalmologyHematologyOncology
Modalities: Small moleculeAntibody-based immunotherapy
Industry: Biotech

Partnerships

NeoTX Therapeutics Ltd.Perelman School of Medicine at University of Pennsylvania

Beyond the preview

Go deeper on Biotech Active.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotech Active.

Explore the full profile